Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma-Reference-Cited by-同舟云学术

Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma

Published:2024-09-13 Issue:1 Volume:29 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Feng Demei¹,Yan Zhimin²,Fu Bibo¹,Bai Shenrui¹,Zhu Lewei³,Gale Robert Peter⁴,Xia Zhongjun¹,Liang Yang¹,Wang Hua¹

Affiliation:

1. State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

2. Department of Hematology, the First Affiliated Hospital of Gannan Medical College, Ganzhou, People’s Republic of China

3. Department of Breast Surgery, The First People’s Hospital of Foshan, Foshan, People’s Republic of China

4. Department of Immunology and Inflammation, Haematology Research Centre, Imperial College London, London, UK

Funder

National Natural Science Foundation of China-Guangdong Joint Fund

Natural Science Foundation of Guangdong Province

Program for Guangdong Introducing Innovative and Entrepreneurial Teams

Sun Yat-sen University Start-Up Funding

National Natural Science Foundation of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2024.2402102

Reference27 articles.

1. Extranodal NK/T cell lymphoma, nasal type: An updated overview

2. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study

3. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study

4. Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available Regimens

5. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study